SUPERVISORY BOARD OF FIRALIS S.A.
As per its form (Société Anonyme) and legal obligations, Firalis S.A. has to have a Supervisory Board to be held at least with three members and has to be organized once every three months, with a mission to execute a constant supervisory control over the company executive management.
In order to benefit from this board at a maximum possible, Firalis has established its Supervisory Board with the legally maximum number of five members and organizes it as often as possible, profiting all mean of communication including tele- and videoconferences.
Supervisory Board discussions are held according to a previously determined agenda, consisting items in need of immediate attention, decision and/or execution; or other items related to mid/long-term company direction.
Members of Firalis' Supervisory Board are :
Mr. Alain GOETZMANN, Chairman
Graduated from the Strasbourg Management School, Alain has had a true entrepreneur life cycle, held various management titles such as Executive Vice President, President and Chief Executive Officer. Alain founded the Alsatian capital-development company Cardinale Développement of which he is still a Partner. Among many Executive Boards in which he is a member, Alain holds the Chairman seat on Delta Inter Management as well as on the Supervisory Board of Firalis S.A.
For more information on Alain GOETZMANN https://alaingoetzmann.com/
represented by CAPITAL GRAND EST, with Mrs. Virginie MIATH as its permanent representative
Virginie MIATH is an Investment Director at Capital Grand Est, holds triple Master degrees from the University Paris-Sud and Groupe INSEEC in Paris, in fields of Genetics, Economy of Innovation, Corporate Finance. She has more than 12 years of in-depth professional experience in various fields around technology transfer, business and finance, including start-up development as well as management of research and investment projects.
Auriga Partners Venture Capital
with Mr. Bernard DAUGERAS, as permenant representer
He is a graduate of the Ecole Polytechnique and a PhD of the University of Orsay, an expert in Life Sciences, took important roles behind several successful investments such as BioAlliance Pharma (EuroNext : BIO) and NicOx (EuroNext : COX). He's a member of the French Academy of Technologies and began his career in research of particle physics at the University of Orsay, the University of California at Berkeley and CNRS, held senior posts at the Ministry of Industry and Research, where he was in charge of promoting technology transfer and relations between research and industry. After 4 years in the Crédit Lyonnais, setting up the Venture Capital arm, he joined Finovelec in 1990.
Dr. Gilles Feutren, Vice Chairman
Dr. Feutren has an MD in immunology (University of Paris 5 - Necker and INSERM U25), and is an acknowledged expert in drug development and biomarker fields. With more than three decades of professional accomplishments in the large pharma, Gilles has remarkable talents in leadership and holds a very significant experience in drug development and approvals; among many others, in particularly within the field of autoimmune diseases and organ transplantation. Gilles has been involved in numerous interactions with health authorities and regulatory agencies such as FDA, EMA and PMDA and masters regulatory steps of approval processes.
He is a contributor and a member of Advisory Board at Firalis SA.
Prof. Olivier DANOS
MD in Genetics and Molecular Biology (University of Paris Orsay), PhD at the Pasteur Institute and University of Paris Didero, Olivier DANOS is a pioneer in the field of gene therapy with a career dedicated to develop life-saving therapies. Current Senior VP and CSO of Regenxbio, former Senior VP of Cell and Gene Therapy at Biogen; over the past twenty years, he has played leadership roles in cell and gene therapy as Director of the Gene Therapy Consortium of the University College of London, at the Necker Hospital - Enfants Malades in Paris, as Chief Scientific Officer of Genethon and as Senior Director of Research at Somatix Therapy Corporation. Also, he has held senior research positions in France, at CNRS (Centre National de la Recherche Scientifique) and Pasteur Institute. He is the former President and a founding member of the European Society of Gene and Cell Therapy.
Prof. Olivier Danos is a founder associate, member of the Supervisory Board and the Chairman of the Scientific Advisory Board of FIRALIS SA.